File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

TitleA multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
Authors
KeywordsBORTEZOMIB PLUS DEXAMETHASONE
INTERNATIONAL STAGING SYSTEM
STEM-CELL TRANSPLANTATION
INDUCTION
MAINTENANCE
Issue Date2020
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-8652
Citation
American Journal of Hematology, 2020, Epub 2020-02-18 How to Cite?
AbstractThe t(14;16) translocation, found in 3%‐5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real‐world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7‐18.7), the median progression‐free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5‐2.4) and 4.1 years (95% CI 3.3‐5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05‐2.58]), as well as revised International Scoring System (R‐ISS) 3 (vs R‐ISS 2; HR = 2.59, 95% CI [1.59‐4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R‐ISS 3 predict poor survival.
Persistent Identifierhttp://hdl.handle.net/10722/281223
ISSN
2019 Impact Factor: 6.973
2015 SCImago Journal Rankings: 1.761
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGoldman‐Mazur, S-
dc.contributor.authorJurczyszyn, A-
dc.contributor.authorCastillo, JJ-
dc.contributor.authorWaszczuk‐Gajda, A-
dc.contributor.authorGrzĄŚko, N-
dc.contributor.authorRadocha, J-
dc.contributor.authorBittrich, M-
dc.contributor.authorKortüm, KM-
dc.contributor.authorGozzetti, A-
dc.contributor.authorUsnarska‐Zubkiewicz, L-
dc.contributor.authorValls, JD-
dc.contributor.authorJayabalan, DS-
dc.contributor.authorNiesvizky, R-
dc.contributor.authorKelman, J-
dc.contributor.authorCoriu, D-
dc.contributor.authorRosiñol, L-
dc.contributor.authorSzukalski, L-
dc.contributor.authorGonzález‐Calle, V-
dc.contributor.authorMateos, MV-
dc.contributor.authorJamroziak, K-
dc.contributor.authorHus, I-
dc.contributor.authorAvivi, I-
dc.contributor.authorCohen, Y-
dc.contributor.authorSuska, A-
dc.contributor.authorChappell, A-
dc.contributor.authorMadduri, D-
dc.contributor.authorChhabra, S-
dc.contributor.authorKleman, A-
dc.contributor.authorHari, P-
dc.contributor.authorDelforge, M-
dc.contributor.authorRobak, P-
dc.contributor.authorGentile, M-
dc.contributor.authorKozłowska, I-
dc.contributor.authorGoldberg, SL-
dc.contributor.authorCzepiel, J-
dc.contributor.authorSilbermann, R-
dc.contributor.authorOlszewski, AJ-
dc.contributor.authorBarth, P-
dc.contributor.authorMikala, G-
dc.contributor.authorChim, CS-
dc.contributor.authorDługosz‐Danecka, M-
dc.contributor.authorGrosicki, S-
dc.contributor.authorVesole, DH-
dc.date.accessioned2020-03-09T09:51:48Z-
dc.date.available2020-03-09T09:51:48Z-
dc.date.issued2020-
dc.identifier.citationAmerican Journal of Hematology, 2020, Epub 2020-02-18-
dc.identifier.issn0361-8609-
dc.identifier.urihttp://hdl.handle.net/10722/281223-
dc.description.abstractThe t(14;16) translocation, found in 3%‐5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real‐world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7‐18.7), the median progression‐free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5‐2.4) and 4.1 years (95% CI 3.3‐5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05‐2.58]), as well as revised International Scoring System (R‐ISS) 3 (vs R‐ISS 2; HR = 2.59, 95% CI [1.59‐4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R‐ISS 3 predict poor survival.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-8652-
dc.relation.ispartofAmerican Journal of Hematology-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectBORTEZOMIB PLUS DEXAMETHASONE-
dc.subjectINTERNATIONAL STAGING SYSTEM-
dc.subjectSTEM-CELL TRANSPLANTATION-
dc.subjectINDUCTION-
dc.subjectMAINTENANCE-
dc.titleA multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma-
dc.typeArticle-
dc.identifier.emailChim, CS: jcschim@hku.hk-
dc.identifier.authorityChim, CS=rp00408-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ajh.25758-
dc.identifier.pmid32072687-
dc.identifier.hkuros309253-
dc.identifier.volumeEpub 2020-02-18-
dc.identifier.isiWOS:000516989700001-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats